Ocera Therapeutics Receives Orphan
Selected Abstract
Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis.
Company to Present at 26th Annual JP Morgan Healthcare Conference SAN DIEGO, Jan. 7 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases, announced ...
January 7, 2008; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis.
|